We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OMCL Falls 20.1% in a Month as Booking and Margin Risks Build
Read MoreHide Full Article
Key Takeaways
Omnicell shares fell 20.1% in four weeks as booking, margin and refresh-cycle risks weighed on the outlook.
OMCL expects $6 million in added memory-chip costs, pressuring product and consolidated gross margins.
Omnicell cut recurring-revenue guidance as some consumables opportunities are taking longer to develop.
Omnicell, Inc. (OMCL - Free Report) shares have fallen 20.1% in the past four weeks, sharpening the debate over whether the pullback has improved the risk-reward setup or reflects pressures that may persist.
The central tension is clear. Omnicell has raised its 2026 profit outlook, but bookings timing, recurring-revenue growth, component costs and the pace of its product refresh remain less predictable.
OMCL’s Earnings Strength Comes With a Caveat
Second-quarter 2026 adjusted earnings were 94 cents per share, up 108.9% year over year and 95.8% above the Zacks Consensus Estimate. Revenues increased 7.4% to $312.2 million and topped the consensus mark by 0.8%.
Per the Zacks Consensus Estimate, OMCL’s 2026 earnings and revenue is pegged at $2.09 and $1.24 billion, respectively.
Image Source: Zacks Investment Research
The quarter also benefited from a one-time $15 million tariff refund. Excluding that benefit, non-GAAP EBITDA would have been $52 million, still above the midpoint of prior guidance. Omnicell raised full-year non-GAAP EPS guidance to $2.15-$2.30 and non-GAAP EBITDA guidance to $175-$185 million.
Omnicell Faces New Pressure on Product Margins
Memory-chip supply-demand imbalances are creating a new cost headwind. Omnicell expects about $6 million of incremental memory-chip costs in the second half of 2026, roughly five times the level anticipated at the beginning of the year.
The company expects those costs to reduce full-year consolidated gross margin by about 50 basis points and product gross margin by roughly 80 basis points. With the tariff refund not recurring, continued component inflation or supply constraints could limit further margin expansion.
OMCL’s Booking Visibility Has Weakened
Omnicell widened full-year product-bookings guidance to $425-$560 million as it reassessed the timing of medium-sized and large hospital transactions. Large automation projects can require broad approvals and take multiple quarters or years to close.
Year-end 2026 annual recurring revenue guidance was reduced to $660-$680 million because some consumables opportunities are taking longer to develop. The slower timing matters because recurring revenue is intended to make Omnicell’s business mix more predictable.
Omnicell’s Refresh Cycle Could Take Longer
Titan XT remains scheduled to ship in the second half of 2026, but the current XT installed base is younger than the G Series base was during the prior transition. That could reduce replacement urgency even as customers evaluate the new platform.
Competition adds another variable. Becton, Dickinson and Company (BDX) markets BD Pyxis medication-management and automated dispensing systems for health systems, while McKesson Corporation (MCK) offers pharmacy-automation technologies for dispensing, packaging and workflow efficiency. Omnicell is entering a major refresh period while customers are making broad platform comparisons.
OMCL’s Valuation Offers a Potential Counterweight
OMCL trades at 1.33X forward 12-month sales, below its five-year median of 1.74X. The multiple is also below the Zacks Medical sector’s 2.24X and the Medical Info Systems sub-industry’s 5.58X.
Image Source: Zacks Investment Research
The discount provides some valuation support, but it does not remove execution risk. A more durable recovery would depend on bookings converting to deployments, recurring revenue improving and the Titan XT refresh translating into revenue over time.
OMCL’s Ratings Still Signal Near-Term Caution
The recent decline has made OMCL less expensive on a sales basis, while the higher 2026 earnings outlook provides an operating offset. Booking uncertainty, memory-chip inflation and refresh-cycle timing still leave the near-term setup unsettled.
OMCL currently carries a Zacks Rank #5 (Strong Sell). Its Growth Score of A, Value Score of B, Momentum Score of B and VGM Score of A indicate favorable characteristics across several investment styles, but the Zacks Rank remains the more important short-term signal because it reflects earnings-estimate revision trends. That combination argues for caution despite the stronger Style Scores.
View the Zacks #1 Rank List
Image: Bigstock
OMCL Falls 20.1% in a Month as Booking and Margin Risks Build
Key Takeaways
Omnicell, Inc. (OMCL - Free Report) shares have fallen 20.1% in the past four weeks, sharpening the debate over whether the pullback has improved the risk-reward setup or reflects pressures that may persist.
The central tension is clear. Omnicell has raised its 2026 profit outlook, but bookings timing, recurring-revenue growth, component costs and the pace of its product refresh remain less predictable.
OMCL’s Earnings Strength Comes With a Caveat
Second-quarter 2026 adjusted earnings were 94 cents per share, up 108.9% year over year and 95.8% above the Zacks Consensus Estimate. Revenues increased 7.4% to $312.2 million and topped the consensus mark by 0.8%.
Per the Zacks Consensus Estimate, OMCL’s 2026 earnings and revenue is pegged at $2.09 and $1.24 billion, respectively.
Image Source: Zacks Investment Research
The quarter also benefited from a one-time $15 million tariff refund. Excluding that benefit, non-GAAP EBITDA would have been $52 million, still above the midpoint of prior guidance. Omnicell raised full-year non-GAAP EPS guidance to $2.15-$2.30 and non-GAAP EBITDA guidance to $175-$185 million.
Omnicell Faces New Pressure on Product Margins
Memory-chip supply-demand imbalances are creating a new cost headwind. Omnicell expects about $6 million of incremental memory-chip costs in the second half of 2026, roughly five times the level anticipated at the beginning of the year.
The company expects those costs to reduce full-year consolidated gross margin by about 50 basis points and product gross margin by roughly 80 basis points. With the tariff refund not recurring, continued component inflation or supply constraints could limit further margin expansion.
OMCL’s Booking Visibility Has Weakened
Omnicell widened full-year product-bookings guidance to $425-$560 million as it reassessed the timing of medium-sized and large hospital transactions. Large automation projects can require broad approvals and take multiple quarters or years to close.
Year-end 2026 annual recurring revenue guidance was reduced to $660-$680 million because some consumables opportunities are taking longer to develop. The slower timing matters because recurring revenue is intended to make Omnicell’s business mix more predictable.
Omnicell’s Refresh Cycle Could Take Longer
Titan XT remains scheduled to ship in the second half of 2026, but the current XT installed base is younger than the G Series base was during the prior transition. That could reduce replacement urgency even as customers evaluate the new platform.
Competition adds another variable. Becton, Dickinson and Company (BDX) markets BD Pyxis medication-management and automated dispensing systems for health systems, while McKesson Corporation (MCK) offers pharmacy-automation technologies for dispensing, packaging and workflow efficiency. Omnicell is entering a major refresh period while customers are making broad platform comparisons.
OMCL’s Valuation Offers a Potential Counterweight
OMCL trades at 1.33X forward 12-month sales, below its five-year median of 1.74X. The multiple is also below the Zacks Medical sector’s 2.24X and the Medical Info Systems sub-industry’s 5.58X.
Image Source: Zacks Investment Research
The discount provides some valuation support, but it does not remove execution risk. A more durable recovery would depend on bookings converting to deployments, recurring revenue improving and the Titan XT refresh translating into revenue over time.
OMCL’s Ratings Still Signal Near-Term Caution
The recent decline has made OMCL less expensive on a sales basis, while the higher 2026 earnings outlook provides an operating offset. Booking uncertainty, memory-chip inflation and refresh-cycle timing still leave the near-term setup unsettled.
OMCL currently carries a Zacks Rank #5 (Strong Sell). Its Growth Score of A, Value Score of B, Momentum Score of B and VGM Score of A indicate favorable characteristics across several investment styles, but the Zacks Rank remains the more important short-term signal because it reflects earnings-estimate revision trends. That combination argues for caution despite the stronger Style Scores.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.